These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 4048012)
1. Central antiserotonergic and antidopaminergic action of pirenperone, a putative 5-HT2 receptor antagonist. Pawłowski L; Siwanowicz J; Bigajska K; Przegaliński E Pol J Pharmacol Pharm; 1985; 37(2):179-96. PubMed ID: 4048012 [TBL] [Abstract][Full Text] [Related]
2. [Role of serotonin and dopamine receptors in the mechanism of action of haloperidol and pirenperone]. Maĭmets MO; Vasar EE; Nurk AM; Allikmets LKh Farmakol Toksikol; 1985; 48(2):15-8. PubMed ID: 3996566 [TBL] [Abstract][Full Text] [Related]
3. The central action of carbamazepine as a potential antidepressant drug. Maj J; Chojnacka-Wójcik E; Lewandowska A; Tatarczyńska E; Wiczyńska B Pol J Pharmacol Pharm; 1985; 37(1):47-56. PubMed ID: 4041037 [TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo characterization of the dopamine D4 receptor, serotonin 5-HT2A receptor and alpha-1 adrenoceptor antagonist (R)-(+)-2-amino-4-(4-fluorophenyl)-5-[1-[4-(4-fluorophenyl)-4-oxobutyl] pyrrolidin-3-yl]thiazole (NRA0045). Okuyama S; Chaki S; Yoshikawa R; Suzuki Y; Ogawa S; Imagawa Y; Kawashima N; Ikeda Y; Kumagai T; Nakazato A; Nagamine M; Tomisawa K J Pharmacol Exp Ther; 1997 Jul; 282(1):56-63. PubMed ID: 9223539 [TBL] [Abstract][Full Text] [Related]
5. The central action of salbutamol, a beta-agonist with a potential antidepressant activity. Przegalinski E; Baran L; Kedrek G Pol J Pharmacol Pharm; 1980; 32(4):485-93. PubMed ID: 6265886 [TBL] [Abstract][Full Text] [Related]
6. Central antiserotonin action of fluperlapine. Maj J; Chojnacka-Wójcik E; Lewandowska A; Tatarczyńska E Pol J Pharmacol Pharm; 1985; 37(4):517-24. PubMed ID: 2867538 [TBL] [Abstract][Full Text] [Related]
7. Some central effects of tiflucarbine, a new potential antidepressant drug. Maj J; Rogóz Z; Sowińska H; Zalewski Z Pol J Pharmacol Pharm; 1987; 39(1):63-74. PubMed ID: 2823240 [TBL] [Abstract][Full Text] [Related]
8. The central action of 1-(2-pyrimidinyl)-piperazine, an ipsapirone metabolite. Tatarczyńska E; Pawłowski L; Chojnacka-Wójcik E; Maj J Pol J Pharmacol Pharm; 1989; 41(1):51-61. PubMed ID: 2587437 [TBL] [Abstract][Full Text] [Related]
9. Serotonergic modulation of footshock induced aggression in paired rats. Datla KP; Mitra SK; Bhattacharya SK Indian J Exp Biol; 1991 Jul; 29(7):631-5. PubMed ID: 1839019 [TBL] [Abstract][Full Text] [Related]
10. Antiserotonin activity of 9-methyl-2-[3-(4-phenyl-1-piperazinylpropyl)]-1,2,3,4-tetrahydro -beta-carbolin-1-one (B-193). Wiczyńska B; Chojnacka-Wójcik E; Rokosz-Pelc A; Mazela H; Przegaliński E Pol J Pharmacol Pharm; 1989; 41(2):169-81. PubMed ID: 2556691 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538 [TBL] [Abstract][Full Text] [Related]
12. The involvement of serotonin in the mechanism of central action of apomorphine. Grabowska M Pol J Pharmacol Pharm; 1976; 28(4):389-94. PubMed ID: 790347 [TBL] [Abstract][Full Text] [Related]
13. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537 [TBL] [Abstract][Full Text] [Related]
14. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184 [TBL] [Abstract][Full Text] [Related]
15. The influence of antiserotonergic agents on the action of dopaminergic drugs. Mogilnicka E; Scheel-Krüger J; Klimek V; Golembiowska-Nikitin K Pol J Pharmacol Pharm; 1977; 29(1):31-8. PubMed ID: 140371 [TBL] [Abstract][Full Text] [Related]
16. A serotonergic component in the central action of 1-(o-methoxyphenyl)-piperazine. Pawłowski L Pol J Pharmacol Pharm; 1983; 35(4):319-26. PubMed ID: 6664937 [TBL] [Abstract][Full Text] [Related]
17. 5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade. Saller CF; Czupryna MJ; Salama AI J Pharmacol Exp Ther; 1990 Jun; 253(3):1162-70. PubMed ID: 2141636 [TBL] [Abstract][Full Text] [Related]
18. The effect of budipine on the central serotoninergic system. Przegaliński E; Bigajska K; Lewandowska A Pol J Pharmacol Pharm; 1982; 34(5-6):309-15. PubMed ID: 7187046 [TBL] [Abstract][Full Text] [Related]
19. [Effect of an imidazobenzodiazepine (RO 15-1788) on aggressive behavior in mice]. Vasar EE; Maĭmets MO; Riago LK; Nurk AM; Allikmets LKh Biull Eksp Biol Med; 1984 Oct; 98(10):441-3. PubMed ID: 6208949 [TBL] [Abstract][Full Text] [Related]
20. Antidepressant activities of WEB 1881, a new nootropic agent. Maj J; Rogóz Z; Skuza G; Sowińska H; Nowak G Pol J Pharmacol Pharm; 1989; 41(5):439-52. PubMed ID: 2561889 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]